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Summary
One goal of aging research is to develop interventions
that combat age-related illnesses and slow aging.
Although numerous mutations have been shown to
achieve this in various model organisms, only a handful
of chemicals have been identified to slow aging. Here, we
report that celecoxib, a nonsteroidal anti-inflammatory
drug widely used to treat pain and inflammation, extends
Caenorhabditis elegans lifespan and delays the age-asso-
ciated physiological changes, such as motor activity
decline. Celecoxib also delays the progression of age-
related proteotoxicity as well as tumor growth in
C. elegans. Celecoxib was originally developed as a
potent cyclooxygenase-2 (COX-2) inhibitor. However, the
result from a structural–activity analysis demonstrated
that the antiaging effect of celecoxib might be indepen-
dent of its COX-2 inhibitory activity, as analogs of celecox-
ib that lack COX-2 inhibitory activity produce a similar
effect on lifespan. Furthermore, we found that celecoxib
acts directly on 3¢-phosphoinositide-dependent kinase-1,
a component of the insulin ⁄ IGF-1 signaling cascade to
increase lifespan.
Key words: 3¢-phosphoinositide-dependent kinase-1;
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Introduction
The identification of chemical interventions that can ameliorate
age-related illness and degeneration has been an important
aspect of current aging research. A drug that can extend life-
span by slowing down the normal aging process may also delay
the progression and the onset of multiple age-related diseases.
The nematode Caenorhabditis elegans has recently been
recognized as an excellent model system for identifying genetic
or pharmacological interventions which alter longevity, mainly
because of its short lifespan and amenability to genetic manipu-
lation. Many genetic pathways that were identified in C. elegans
to regulate longevity turned out to be evolutionarily conserved.
For example, mutations inhibiting the insulin ⁄ IGF-1-like signal-
ing (IIS) have been shown to extend lifespan and delay various
age-related physiological changes (Guarente & Kenyon, 2000;
Garigan et al., 2002; Herndon et al., 2002; Kenyon, 2005). The
IIS pathway is highly conserved and has been shown to influence
longevity in model organisms ranging from worms to mice
(Kenyon, 2010). In addition, a number of compounds have
been reported to extend lifespan in worms. These include a
sirtuin activator resveratrol (Wood et al., 2004; Bass et al.,
2007), an antihyperglycemic drug metformin (Onken & Driscoll,
2010), a variety of antioxidants (e.g. vitamin E) (Harrington &
Harley, 1988; Adachi & Ishii, 2000; Melov et al., 2000), and
several serotonin receptor antagonists (e.g. mianserin), as well
as anticonvulsant medicines (e.g. ethosuximide) that affect
neuronal activity (Evason et al., 2005, 2008; Petrascheck et al.,
2007). Here, we report that the anti-inflammatory drug cele-
coxib and its derivatives significantly extend C. elegans lifespan
and delay the onset of age-associated proteotoxicity and tumor
growth.
Since the discovery and introduction of aspirin more than a
century ago, nonsteroidal anti-inflammatory drugs (NSAIDs)
have become the most widely used therapeutic agents in the
treatment of conditions such as pain, fever, and inflammation.
NSAIDs act primarily by inhibiting cyclooxygenase (COX),
thereby blocking the formation of prostaglandins (PGs) in normal
and inflamed tissues. Cyclooxygenase exists as two distinct
isoforms. While COX-1 is constitutively expressed in most tissues,
COX-2 is expressed in inflamed tissues in response to proinflam-
matory stimuli (Diaz et al., 1998; Lipsky, 1999; Dannenberg
et al., 2001). Celecoxib (Celebrex) (Fig. 1A) is one of the selec-
tive inhibitors of COX-2 that were originally developed as a new
class of NSAID to reduce the gastrointestinal toxicities that are
associated with COX-1 blockage. In addition to their potent anti-
inflammatory and analgesic effects, long-term use of different
NSAIDs (including celecoxib) have been reported to reduce the
risk and delay the onset of various age-related diseases, includ-
ing cancers (Thun et al., 1991; Smalley & DuBois, 1997; Thomp-
son et al., 1997; Fukutake et al., 1998; Hida et al., 1998; Kismet
et al., 2004), Alzheimer’s disease, and other neurodegenerative
diseases (in t’ Veld et al., 2001; Aisen, 2002; Etminan et al.,
2003; Asanuma et al., 2004). Studies in our laboratory have
now further linked the drug to normal aging. Interestingly, while
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the primary target of celecoxib in clinical uses is COX-2, our
results suggest that celecoxib might extend C. elegans lifespan
via a mechanism that is independent of COX-2 but share similar
phenotypic features as IIS pathway mutants. The lifespan exten-
sion resulting from celecoxib treatments requires the activity of
DAF-16, the FOXO transcription factor known to regulate devel-
opment and longevity in response to IIS (Lin et al., 1997). Our
data also suggest that celecoxib might extend lifespan by inhibit-
ing the kinase activity of 3-phosphoinositide-dependent kinase-
1 (PDK-1), a key component of the IIS cascade.
Results
Celecoxib treatment extends C. elegans lifespan and
delays the age-related decline of motor activity
One goal of aging studies is to identify drugs that can slow aging
and delay age-related illness and degeneration. To identify com-
pounds that might slow aging and extend lifespan in C. elegans,
we assayed a panel of randomly selected compounds that have
known effects on human physiology. Animals grown on agarose
plates were exposed to each drug at two different concentra-
tions from hatching. To ensure that the drugs retained their
potency throughout the entire experiment, animals were trans-
ferred to fresh plates with drugs every 2–4 days. Among those
examined, celecoxib (Fig. 1A) had the greatest effect on longev-
ity, extending adult mean lifespan by up to 20% (Fig. 1B;
Table S1, Supporting information). Results from our dose–
response analysis indicated that animals treated with external
concentrations of 10 and 2 lM celecoxib displayed the largest
lifespan extension at 20 C (Fig. 1C; Table S1, Supporting infor-
mation). Animals exposed to either higher or lower concentra-
tions of celecoxib exhibited a smaller or an insignificant lifespan
extension (Fig. 1C; Table S1, Supporting information). More-
over, the longevity effect of celecoxib was not temperature sen-

















































































Fig. 1 Celecoxib extends adult lifespan and delays age-associated physiological changes. (A) Chemical structure of celecoxib. (B) Survival curves of wild-type (N2)
animals treated with either DMSO control (blue) or 10 lM of celecoxib (red). The treatments were initiated from the time of hatching and continued until death.
Statistical details and repetition of this experiment are summarized in Table S1 (Supporting information). (C) Dosage–response analysis of celecoxib (Cbx). Wild-
type (N2) animals were exposed to DMSO control or 0.5, 2, 10, and 50 lM celecoxib. The average percentage change in lifespan of at least two independent
experiments was plotted as a function of dosage. Statistical details and repetition of this experiment are summarized in Table S1 (Supporting information).
(D) Survival curves of wild-type (N2) animals exposed to adult-only treatment of either DMSO control (blue) or 2 lM of celecoxib (red). The treatments were
initiated from the first day of adulthood and continued until death. (E) The speed of spontaneous locomotion of wild-type (N2) animals treated with either DMSO
control (blue) or 10 lM of celecoxib (red). Locomotion speed was quantified every other day until death as previously described (Hsu et al., 2009), and the mean
locomotion speed of these worms was plotted as a function of age. Error bars represent SD. Locomotion speed decayed throughout lifespan and can be best fitted
by first-order exponential decay, and the rate of the decay (DMSO control, rate = 0.2686, R2 = 0.9623; celecoxib, rate = 0.1179, R2 = 0.9931) was calculated
using the method previously described (Hsu et al., 2009).
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(Table S1, Supporting information). The rate of age-associated
motor activity decline has been shown to be a prominent predic-
tor of lifespan as well as a great physiological parameter of ani-
mals’ healthiness (Hsu et al., 2009).Thus, we examined the
locomotion speed of celecoxib-treated animals throughout the
entire lifespan. Our result showed that the rate of the motor
activity decay (DMSO control, rate = 0.2686; celecoxib, rate =
0.1179) is significantly reduced in celecoxib-treated worms
(Fig. 1E), indicating that both healthspan and lifespan are
increased when worms are exposed to long-term celecoxib
treatments.
It has been reported that C. elegans lifespan can be extended
by feeding the worms with dead bacteria, which would reduce
their susceptibility to bacterial infections (Garigan et al., 2002).
Therefore, it is possible that celecoxib may exert its longevity
effect by killing the bacteria, instead of acting directly on the
worms. To test this possibility, we examined the effects of celec-
oxib on the growth of two commonly used bacteria strains,
OP50 and HT115. The results indicate that the growth of OP50
and HT115 was completely unaltered when exposed to celecox-
ib (Fig. S1, Supporting information).
In C. elegans, signaling pathways that regulate longevity
have been suggested to have different temporal requirements
to regulate longevity. For instance, the IIS functions during early
adulthood to regulate longevity (Dillin et al., 2002a). Con-
versely, mitochondrial respiration functions during larval devel-
opment to influence longevity (Dillin et al., 2002b). We found
that the lifespan-extending effect of celecoxib treatment
initiated at the first day of adulthood is comparable to
those initiated from hatching (Fig. 1D; Table S1, Supporting
information). This finding suggests that exposure to celecoxib
only during adulthood is sufficient to produce the antiaging
effect.
Celecoxib further extends the lifespan of animals
with reduced food uptake and mitochondrial
respiration
To determine whether celecoxib extends lifespan via biological
processes previously known to modulate aging in C. elegans,
we next tested the effect of combining celecoxib treatment and
various mutations that alter lifespan. Dietary restriction (DR) is
known to extend lifespan in a wide range of species (Masoro,
2005) and can be mimicked by the mutations of eat-2 gene that
is required for pumping food into the pharynx (Lakowski & Hek-
imi, 1998). Therefore, we first examined whether the lifespan of
eat-2(ad1116) mutants can be further extended by celecoxib.
Treatments with celecoxib significantly extended the lifespan of
eat-2 mutants by 17% (Fig. 2A; Table S1, Supporting informa-
tion). The FoxA transcription factor PHA-4 has been previously
shown to be required for eat-2 mutations to extend lifespan in
worms (Panowski et al., 2007). Treatments with celecoxib also
extended the lifespan of pha-4(zu225) mutants to a similar
extent (Table S1, Supporting information). Moreover, the rate
of pumping (eating) was not affected in celecoxib-treated
animals [Day 1 adult pumping rate: control, 282 ± 22 min)1;
celecoxib, 276 ± 24 min)1; n = 15; P = 0.54], indicating that
celecoxib may not exert its effects via changes in appetite or
food limitation. Together, our results suggest that DR is not the
primary mechanism underlying the antiaging effect of celecoxib.
Reduction in the mitochondrial respiration by RNA interfer-
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Fig. 2 Celecoxib extends adult lifespan in a daf-16-dependent manner. Survival curves of N2 animals and (A) eat-2(ad1116), (B) cyc-1(RNAi), (C) daf-16(mu86),
or (D) daf-2(e1370) mutants grown on plates containing DMSO control (blue or green) or 2 lM of celecoxib (red or orange). All drug treatments were initiated
from the first day of adulthood and continued until death, except cyc-1(RNAi). In all cases, these data represent the results of a single trial. Repetition of this
experiment and statistical details are summarized in Table S1 (Supporting information).
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2002b). To investigate whether celecoxib plays a role in the
mitochondrial respiration to influence longevity, we treated the
worms grown on cyc-1 RNAi bacteria with celecoxib. Exposure
to celecoxib further extended the lifespan of cyc-1 (RNAi) ani-
mals by 17% (Fig. 2B; Table S1, Supporting information). This
finding suggests that celecoxib may not influence longevity by
reducing mitochondrial respiratory chain activity.
Celecoxib extends lifespan in a daf-16-depedent
manner
Mutations affecting the IIS pathway have been shown to
influence C. elegans lifespan (Kenyon et al., 1993; Larsen
et al., 1995; Morris et al., 1996; Kimura et al., 1997; Lin
et al., 1997; Ogg et al., 1997; Ogg & Ruvkun, 1998; Paradis
& Ruvkun, 1998; Paradis et al., 1999). For example, animals
carrying reduction-of-function mutations in daf-2, a homolog
of human insulin ⁄ IGF-1 receptor, or mutations in components
of its downstream PI3K ⁄ PDK-1 ⁄ AKT signaling pathway, are
significantly long-lived (Panowski & Dillin, 2009; Kenyon,
2010). The FOXO transcription factor DAF-16 is required for
IIS mutations to extend lifespan (Kenyon et al., 1993; Lin
et al., 1997; Ogg et al., 1997). Thus, we next examined
whether daf-16 is also required for celecoxib to influence lon-
gevity. We found that treatment with celecoxib failed to
extend the lifespan of animals carrying a null mutation of daf-
16 (Fig. 2C; Table S1, Supporting information), suggesting
that celecoxib may influence longevity by inhibiting a compo-
nent of the IIS pathway upstream of DAF-16 or by activating
DAF-16 directly. We have also tested the effect of celecoxib
on daf-2mutants and found no significant lifespan extension
(Fig. 2D; Table S1, Supporting information). Again, this sup-
ports the idea that celecoxib may extends lifespan by modu-
lating the IIS pathway activity.
Celecoxib extends lifespan via a mechanism
independent of its COX-2 inhibitory activity
Although celecoxib was originally developed as a potent COX-2
inhibitor, our finding that celecoxib extends lifespan in a daf-16-
dependent manner raises the possibility that the longevity effect
of celecoxib may be independent of its COX-2 inhibitory activity.
The reason is twofold. First, in mammalian models, celecoxib is
known to have additional cellular targets. For instance, several
studies have suggested that celecoxib might inhibit tumor
growth, at least in part, by acting on a COX-2-independent
mechanism, when treated at a higher dosage (e.g. IC50 = 40 nM
for COX-2 inhibition; > 20 lM for apoptosis induction) (Hsu
et al., 2000; Kismet et al., 2004; Zhu et al., 2004). More impor-
tantly, no COX isoforms have been identified in unicellular
organisms, the plant kingdom, insects, and nematodes, includ-
ing C. elegans (Simmons et al., 2004).
To investigate whether the longevity activity of celecoxib can
be dissociated from its COX-2 inhibitory activity, we analyzed
the lifespan of animals exposed to OSU-03012, a close structural
























































Fig. 3 OSU-03012, a derivative of celecoxib, also extends lifespan. (A) Chemical structure of the celecoxib derivative, OSU-03012. (B) Survival curves of wild-type
(N2) animals treated with either DMSO control (blue) or 0.5 lM of OSU-03012 (red). The treatments were initiated from the time of hatching and continued until
death. Statistical details and repetition of this experiment are summarized in Table S2 (Supporting information). (C) Dosage–response analysis of OSU-03012
(OSU). Wild-type (N2) animals were treated with DMSO control or 0.01, 0.05, 0.5, 5, and 10 lM OSU-03012. The average percentage change in lifespan was
plotted as a function of dosage. Statistical details and repetition of this experiment are summarized in Table S2 (Supporting information). (D) Survival curves of
wild-type (N2) animals exposed to an adult-only treatment of either DMSO control (blue) or 0.5 lM of OSU-03012 (red). The treatments were initiated from the
first day of adulthood and continued until death.
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inhibitory activity up to 50 lM (Zhu et al., 2004). Treatment with
OSU-03012 significantly extends worm lifespan to an extent
similar to that of celecoxib when initiated from hatching
(Fig. 3B; Table S2, Supporting information). Wild-type animals
treated with 0.5 lM OSU-03012 displayed the largest lifespan
extension (Fig. 3C; Table S2, Supporting information). Adult-
only treatment of 0.5 lM OSU-03012 displayed an even greater
lifespan extension (35%) (Fig. 3D; Table S2, Supporting infor-
mation). Similar to what we have observed with celecoxib, expo-
sure to OSU-03012 further extends the lifespan of eat-
2(ad1116) and cyc-1 (RNAi) mutants, but not the lifespan of
daf-16(mu86)and daf-2(e1370) mutants (Fig. 4A–D; Table S2,
Supporting information). As OSU-03012 exhibits no detectable
COX-2 inhibitory activity, our findings strongly suggest that cel-
ecoxib and its derivative OSU-03012 act on a target other than
COX-2 to modulate longevity in C. elegans. It should be noted
that we could not rule out the possibility that different mutants
may exhibit varied sensitivity to the drugs. However, this is unli-
kely to be the case, as daf-16(mu86) mutants failed to respond
to all three different concentrations of OSU-03012 we have
examined (Table S2, Supporting information).
Celecoxib and OSU-03012 might extend lifespan by
inhibiting PDK-1 activity
Among all the potential secondary targets reported to date [e.g.
PDK-1, Bcl-2, PPAR-d (Kismet et al., 2004)], inhibition of PDK-1,
a known IIS pathway component upstream of DAF-16, by celec-
oxib is particularly intriguing. It has been reported that celecoxib
and a number of its derivatives exhibit different degrees of inhib-
itory activity against human PDK-1 (e.g. celecoxib, IC50 = 48 lM;
OSU-03012, IC50 = 5 lM) (Zhu et al., 2004). Given the strong
antagonistic activity of OSU-03012 on human PDK-1 both
in vitro and in vivo (Zhu et al., 2004), we have also tested the
effect of OSU-03012 on pdk-1 mutants’ lifespan. Treatment
with OSU-03012 failed to extend the lifespan of either the long-
lived loss-of-function pdk-1(sa680) mutants or the short-lived
gain-of-function pdk-1(mg142) mutants (Paradis et al., 1999)
(Fig. 4E; Table S2, Supporting information).
To determine whether the activity of C. elegans PDK-1 could
indeed be inhibited by celecoxib and OSU-03012 in vivo, we
analyzed the phosphorylation status of SGK-1 (serum- and glu-





















































































Fig. 4 OSU-03012 extends lifespan via a DAF-16 and 3¢-phosphoinositide-dependent kinase-1 (PDK-1)-dependent mechanism. Survival curves of N2 animals and
(A) eat-2(ad1116), (B) cyc-1(RNAi), (C) daf-16(mu86), (D) daf-2(e1370),(E) pdk-1(mg142), or pdk-1(sa680) mutants grown on plates containing DMSO control
(blue or green) or 0.5 lM of OSU-03012 (red or orange). pdk-1(mg142) is a gain-of-function (gf) mutation of pdk-1, whereas pdk-1(sa680) is a loss-of-function ())
mutation of pdk-1. In all cases, these data represent the results of a single trial. Repetition of this experiment and statistical details are summarized in Table S2
(Supporting information).
Celecoxib extends C. elegans lifespan, T-T. Ching et al.
ª 2011 The Authors
Aging Cell ª 2011 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland
510
animals exposed to both drugs. It has been reported that the
Thr256 residue in the activation loop of human SGK1 is phos-
phorylated by PDK1 (Tessier & Woodgett, 2006), whereas the
Ser422 residue in the hydrophobic motif might be phosphory-
lated by mTOR (Hong et al., 2008). The phosphorylation status
of SGK-1 is assessed by immunoprecipitating SGK-1::Green
Fluorescence Protein fusion proteins from drug-treated BR2773
animals (i.e. a transgenic strain–expressing SGK-1::GFP) and
blotting with anti-phospho-Thr, anti-phospho-Ser, or anti-phos-
pho-(Ser ⁄ Thr)PDK-1 docking motif antibodies. We found that
treatments with both drugs significantly reduce Threonine phos-
phorylation of SGK-1 by PDK-1, while serine phosphorylation of
SGK-1 remains basically unaltered (Fig. 5). Thus, our findings
strongly suggest that celecoxib and OSU-03012 might act
directly on PDK-1 or a component upstream of PDK-1 in the IIS
pathway to increase longevity in worms.
Celecoxib and OSU-03012 treatments enhance
DAF-16 activity
Previous studies have shown that DAF-16 accumulates in the
nucleus when the activity of its upstream kinases is reduced
(Henderson & Johnson, 2001; Lin et al., 2001). To further
examine the idea that celecoxib and OSU-03012 might act on
a component of the IIS pathway upstream of DAF-16, likely
PDK-1, to influence longevity, we examined the nuclear locali-
zation of DAF-16 using a GFP reporter strain (TJ356) (Hender-
son & Johnson, 2001). In agreement with our model, we found
an increased level of nuclear-localized DAF-16::GFP fusions
after 72 h of treatment with celecoxib or OSU-03012 (Fig. 6A–
B), indicating that celecoxib and OSU-03012 treatments might
promote DAF-16 activation. Interestingly, we have also
observed a higher level of nuclear-localized DAF-16::GFP in the
anterior end compared with the posterior end of the animals
(Fig. 6A). This may presumably be because of the way worms
absorb the drugs (i.e. pumping via pharynx). Because it is possi-
ble that the nuclear-localized DAF-16 is not fully activated, we
also measured the expression level of sod-3, a known daf-16
target gene involved in stress responses, by qRT-PCR (Honda &
Honda, 1999). The expression of sod-3 significantly increased
in animals exposed to celecoxib or OSU-03012 for 72 h
(Fig. 6C).
In addition to regulating longevity, the IIS and DAF-16 also
control entry into an alternative developmental state, named
dauer in C. elegans (Morris et al., 1996; Kimura et al., 1997; Lin
et al., 1997). The dauer is a growth-arrested, stress-resistant
alternative larval stage that is induced by food limitation, high
temperatures, and crowding. Strong daf-2 alleles enter dauer
stage without any environmental cues, while weak daf-2 alleles
(e.g. e1370) enhance dauer formation only at high temperature
(Fig. 6D). To examine the ability of OSU-03012 to promote dau-
er formation, we exposed the daf-2(e1370) mutants to the drug
from hatching and analyzed the dauer formation. We found
that OSU-03012 treatment increased dauer formation of daf-
2(e1370) mutants at 22.2 C from 35% of untreated animals to
62% (Fig. 6D), suggesting that treatment of OSU-03012 can
further lower the IIS pathway activity in a sensitized daf-
2(e1370) background. Together, our results are consistent with
a model that celecoxib and OSU-03102 act on a component of
the IIS pathway, most likely PDK-1, to extend C. elegans life-
span.
Celecoxib and OSU-03012 treatments ameliorate
age-associated illness
An intriguing question in biology is how the normal aging pro-
cess is coupled to age-related diseases. Could a drug that
extends lifespan also delay the onset of age-related diseases?
Reducing IIS pathway activity has been shown to ameliorate the







































Fig. 5 Effect of celecoxib and OSU-03012 on 3¢-phosphoinositide-dependent kinase-1 (PDK-1) activity. (A–B) The in vivo kinase activity of PDK-1 was assessed by
measuring the phosphorylation status of SGK-1, a known substrate of PDK-1. Whole worm extracts were prepared from transgenic animals–expressing SGK-
1::GFP fusion proteins (BR2773) treated with DMSO control, 10 lM celecoxib, or 0.5 lM OSU-03012 from hatching. Extracts were made from synchronized Day 1
adult worms and subjected to immunoprecipitation using anti-GFP antibodies. The immunoprecipitates were then immunoblotted using anti-GFP, anti-phospho-
Thr, anti-phospho-Ser, or anti-phospho-(Ser ⁄ Thr) PDK-1 docking motif antibodies. The blots shown in (A) represent the result of a single experiment. The average
of three independent experiments was quantified and presented in (B). The relative phosphorylation status of SGK-1 was analyzed by densitometry using IMAGEJ
1.37 software (NIH, Bethesda, MD, USA ). *Significant changes (P < 0.05). P values were calculated by unpaired Student’s t-test.
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ation associated with aberrant protein aggregations (e.g. Alzhei-
mer’s and Huntington’s disease) as well as tumor growth in
C. elegans disease models (Morley et al., 2002; Hsu et al.,
2003; Cohen et al., 2006; Pinkston et al., 2006). For instance,
YFP fusions containing 35 glutamine repeats (Q35-YFP)
expressed in the body wall muscle cells form aggregates and
cause mobility loss as the animals age (Morley et al., 2002). Both
the formation of polyQ aggregates and its proteotoxicity are
delayed in long-lived IIS pathway mutants and accelerated in
short-lived IIS pathway mutants (Morley et al., 2002; Hsu et al.,
2003). To test whether OSU-03012 treatment can also amelio-
rate the aggregation-associated proteotoxicity by inhibiting the
IIS pathway in a worm model, we first analyzed the age-depen-
dent formation of polyQ aggregates in drug-treated animals.
We found that the formation of polyQ aggregates in animals
exposed to OSU-03012 is delayed compared to the control
animals (Fig. 7A). The aggregation-associated proteotoxicity is
also significantly ameliorated in OSU-03012-treated animals
(Fig. 7B).
Mutations in gld-1, a tumor suppressor gene required for
oocyte development in C. elegans, causes lethal germ line




































































Fig. 6 OSU-03012 alters the nuclear localization and the activity of DAF-16. (A) Nuclear accumulation of DAF-16 induced by OSU-03012 treatment. Images of
TJ356 animals, which carry an integrated daf-16::gfp array in a wild-type background, exposed to either DMSO control or 0.5 lM of OSU-03012 for 72 h. (B)
Quantification of the nuclear accumulation of DAF-16::GFP in response to 10 lM celecoxib and 0.5 lM OSU-03012 treatments. Worms were scored for the
presence or absence of GFP accumulation within the intestinal nuclei at the first day of adulthood (n ‡ 120 for each treatment). An animal was scored as having
nuclear DAF-16 if more than one intestinal nucleus contained DAF-16-GFP. RNA interference treatment by feeding of daf-2 was also performed as a positive
control. Lifespan following each drug treatment were determined to confirm the effectiveness of the drug treatment. (C) Effects of celecoxib and OSU-03012 on
DAF-16 transcriptional activity. Wild-type N2 animals were exposed to DMSO control, 10 lM celecoxib, or 0.5 lM OSU-03012 from hatching. Relative mRNA levels
of sod-3 of these animals were measured by quantitative RT-PCR, and the mean of three different sample sets is shown. The relative mRNA levels were normalized
against act-1 (beta-actin) levels. Error bars: ±SD. (D) daf-2(e1370) mutants (P0) were exposed to DMSO control or 0.5 lM OSU-03012 at 20 C. The F1 eggs were
then moved to the different temperatures indicated for 72 h before being scored for dauer formation. Each bar represents combined data of three independent
experiments per condition (n ‡ 150 for each treatment). Asterisks indicate significant changes (*P < 0.005). P values were calculated by Pearson’s chi-square test.
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significantly suppressed in long-lived IIS pathway mutants (Pink-
ston et al., 2006). To examine whether the progression of germ
line tumor growth in gld-1 mutants could be delayed by celecox-
ib and OSU-03012, we monitored the growth of germ line
tumors in drug-treated mutants. As predicted, the growth of
the germ line tumors in gld-1 mutants is inhibited by celecoxib
and OSU-03012 treatments, presumably by inhibiting PDK-1
activity (Fig. 7C–D). The inhibitory effects of these drugs on the
proliferation of germ line cells appears to occur only when gld-1
is mutated, because both the brood size and the length of the
reproductive period in N2 animals are not altered by celecoxib
treatment (Fig. S2, Supporting information). Interestingly, both
of these compounds have been proposed as a cancer chemopre-
vention drug. Our findings have demonstrated that celecoxib, a
compound widely used as an anti-inflammatory drug in humans,
extends lifespan and delays the progression of age-related pro-
teotoxicity and tumor growth in C. elegans.
Discussion
In this study, we report that celecoxib, a NSAID, extends both
mean and maximum lifespan in C. elegans. Furthermore, the
physical healthiness, as indicated by the age-associated decay
rate of motor activity (Hsu et al., 2009), is significantly improved
in celecoxib-treated animals. The effect of celecoxib on aging is
not a result of a change in the nutritional value of the bacteria,
because celecoxib has no effect on bacteria growth (Fig. S1,
Supporting information). These findings prompt one critical
question: What is the mechanism of action by which celecoxib
extends lifespan? Celecoxib was originally developed as a selec-
tive COX-2 inhibitor for the treatments of pain and inflamma-
tion. Therefore, one might naturally predict celecoxib to extend
lifespan via a mechanism involving reduced COX activity. How-
ever, several lines of evidence suggest that the lifespan-extend-
ing effect of celecoxib is independent of its COX-2 inhibitory
activity. First, no homolog of mammalian COXs have been iden-
tified in unicellular organisms, the plant kingdom, insects, and
nematodes, including C. elegans (Simmons et al., 2004). We
have also performed our own search for a C. elegans homolog
of mammalian COXs using bioinformatics approaches based on
sequence homology and failed to identify any COX isoforms in
C. elegans. Secondly, results from our structural–activity analysis
demonstrated that the antiaging effect of celecoxib is likely to






































































Fig. 7 OSU-03012 delays the progression of age-related diseases. (A) OSU-03012 delays the accumulation of polyQ aggregates. The number of polyQ
aggregates in Q35 animals treated with DMSO control (blue) or 0.5 lM of OSU-03012 (red) was scored and plotted as a function of age. Under each condition,
10–15 worms were randomly selected from a pool of > 200 worms and counted for aggregates every day. Data are mean ± SD. (B) Relative locomotion speed of
Q35 animals treated with DMSO control (blue) or 0.5 lM of OSU-03012 (red). Locomotion speed was quantified every day as previously described, and the mean
locomotion speed was plotted as a function of age. Data are mean ± SD as a percentage of day 1 DMSO control. (C) Images of day 6 adult wild types (left panel)
or gld-1(RNAi) (right panel) animals stained with the DNA-intercalating dye 4¢,6¢-diamidino-2-phenylindole (DAPI) using standard method. The gonad of wild-type
animal was outlined by white dashed line. The white arrows indicate the presence of undifferentiated germ cells outside of the gonad in gld-1(RNAi) mutants. (D)
Worms exposed to DMSO control, 10 lM celecoxib, or 0.5 lM OSU-03012 from hatching were scored for the presence or absence of undifferentiated germ cells
outside of the gonad as shown in the right panel of (C) at day 6 of adulthood (n ‡ 125 for each treatment). The percentage of animals with undifferentiated germ
cells found in the head is plotted here. Each bar represents combined data of 2–4 independent experiments per condition. Mean ± SD = 60.4 ± 3.3, 45.0 ± 1.7,
and 46.2 ± 2.6 for DMSO, cbx, and OSU-03012, respectively. Asterisks indicate significant changes (**P < 0.005, *P < 0.05). P values were calculated by
Pearson’s chi-square test.
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analog of celecoxib that completely lacks COX-2 inhibitory activ-
ity produces a similar effect on lifespan (Fig. 3–4). Finally, celec-
oxib is known to affect the activity of other proteins at a higher
dosage in the mammalian system. For instance, several studies
have suggested that celecoxib might induce apoptosis and inhi-
bit tumor growth, at least in part, by acting on a COX-2-inde-
pendent mechanism (Hsu et al., 2000; Kismet et al., 2004; Zhu
et al., 2004). However, the dosage required to induce apoptosis
is significantly higher than the dosage required for COX-2 inhibi-
tion (i.e. IC50 = 40 nM for COX-2 inhibition; > 20 lM for apop-
tosis induction). Nevertheless, in the absence of its primary
target (i.e. COXs), it is plausible that celecoxib acts on one of the
secondary targets to produce the longevity effects in C. elegans.
In C. elegans, a number of environmental and physiological
signals have been shown to influence longevity (Kenyon, 2010).
Reduction in food intake, mitochondrial respiration activity, IIS,
and signals from the germ line cells have all been reported to
extend worm lifespan (Kenyon, 2010). The results of our genetic
studies shown here have revealed the relationship between cel-
ecoxib and these known pathways. First, our results indicate
that celecoxib and its derivative OSU-03012 do not influence
longevity by acting on the mechanism that mediates DR
response (Figs 2A and 4A). It also appears that celecoxib and its
derivatives do not influence longevity by altering the mitochon-
drial respiratory chain activity (Figs 2B and 4B). Interestingly, we
found that, in modulating C. elegans lifespan, celecoxib and its
derivatives are completely dependent on the activity of the
FOXO transcription factor DAF-16 (Figs 2C and 4C). Consis-
tently, we have found that worms exposed to celecoxib or OSU-
03012 exhibit an increased level of nuclear-localized DAF-16,
increased expression of DAF-16 target genes, and enhanced
dauer formation (Fig. 6). Together, these findings strongly sug-
gest that chronic treatments of celecoxib and its derivatives may
extend lifespan by modulating the IIS pathway and DAF-16
activity.
In mammals, it has been shown that celecoxib inhibits
mammalian PDK-1 activity, a known IIS pathway component,
at higher dosages (Zhu et al., 2004). A number of celecoxib
derivatives, including OSU-03012, have also been reported
to exhibit different degrees of inhibitory activity against
mammalian PDK-1, while lacking COX-2 inhibitory activity
(Zhu et al., 2004). In C. elegans, PDK-1 is known to function
in the IIS pathway to control longevity, development, and
metabolism (Paradis et al., 1999). A reduction-of-function
mutation in pdk-1 results in increased lifespan (Paradis et al.,
1999). Therefore, given the known role of PDK-1 in IIS and
lifespan regulation, it has emerged to be the most likely
physiological target of celecoxib and OSU-03012 in influenc-
ing worm aging. Indeed, treatments with OSU-03012 failed
to extend the lifespan of both pdk-1(sa680) and pdk-
1(mg142) mutants (Fig. 4E), suggesting that these drugs may
exert their effects by altering PDK-1 activity. Thus, when
PDK-1 is mutated, the longevity effects of these compounds
are compromised. At the molecular lever, both sa680 and
mg142 alleles contain a missense mutation located in the
kinase domain of PDK-1, in close proximity to one another
[i.e. sa680, G255R; mg142, A263V (Paradis et al., 1999)].
The PDK1 kinase domain has at least three ligand-binding
sites; the ATP-binding pocket, the peptide substrate-binding
site, and a groove in the N-terminal lobe that binds its
kinase substrates. Many inhibitors of PDK-1 were designed
or screened to target these sites to compete with either the
substrates or ATP (Bobkova et al., 2010). In fact, celecoxib
and OSU-03012 have been proposed to inhibit mammalian
PDK-1 through competition with ATP (Zhu et al., 2004).
Thus, mutations such as mg142 or sa680 that would likely
change the tertiary structure of the kinase domain may very
well alter the PDK-1 inhibitory activity of a compound. Fur-
thermore, we have shown that in vivo PDK-1 activity is sig-
nificantly reduced in celecoxib- or OSU-03012-treated
animals (Fig. 5). Together, our findings support the model
that celecoxib and OSU-03012 function as PDK-1 inhibitors
to increase longevity in worms. Alternatively, celecoxib may
act on a component upstream of PDK-1 in the IIS pathway
or act on an unknown target that indirectly alters IIS and
PDK-1 activity. However, the latter model is less preferable
because it has been shown that celecoxib and OSU-03012
can directly inhibit mammalian PDK-1 activity in vitro (Zhu
et al., 2004).
In addition to longevity and dauer formation, the IIS pathway
has been shown to influence many other aspects of worm physi-
ology, such as developmental timing, reproduction, feeding
rate, and fat storage (Kenyon et al., 1993; Kimura et al., 1997;
Gems et al., 1998). However, we have observed no significant
differences in fecundity (Fig. S2, Supporting information) and
developmental timing [egg to egg time: control, 70.0 ± 1.4 h;
celecoxib, 70.2 ± 1.5 h; P = 0.68] between the drug-treated
and control animals. Furthermore, it has been reported that the
lifespan of the hypomorphic daf-2(e1370) mutants can be fur-
ther extended by daf-2 RNAi (Arantes-Oliveira et al., 2003).
However, only a small (7–9%), but not statistically significant,
extension of lifespan has been observed in daf-2(e1370)
mutants when treated with OSU-03012 (Fig. 4D; Table S2, Sup-
porting information). Similarly, compared with the robust
effects of mutations in the IIS pathway (e.g. daf-2 or pdk-1) on
longevity (> 100%), the effects of celecoxib and OSU-03012 are
rather small (20%). The reason why these drug treatments did
not completely phenocopy daf-2 or pdk-1 mutations may be
twofold. First, the maximum level of inhibition of IIS activity that
could be achieved by the drug treatments may be limited by
other detrimental secondary effects associated with these com-
pounds (e.g. secondary targets), as exposure of the animals to
high doses of these drugs do cause lethality (Figs 1C and 3C).
For instance, the external concentration of OSU-03012 that pro-
duced the optimal longevity effect (i.e. 0.5 lM) is much lower
than the reported IC50 of the compound for PDK-1 inhibition
(i.e. 5 lM) (Zhu et al., 2004). The internal concentration of the
drug is likely to be even lower. Therefore, the effects of the
drugs we observed on worm physiology may be suboptimal
compared with other IIS mutants or RNAi. Second, as we men-
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tioned earlier, we have observed a higher level of nuclear-local-
ized DAF-16::GFP in the anterior end compared with the poster-
ior end of the animals (Fig. 6A). This may presumably be
because of the way worms absorb the drugs (i.e. pumping via
pharynx). Therefore, it is possible that the effects we observed
with these drugs are limited by the number and the types of cells
they can reach. This may explain why certain aspects of worm
physiology are not affected by the drug treatments.
It has been proposed that mild stresses early in life may
causes a lifespan extension by enhancing the existing damage
repair mechanisms (Rattan, 2008). This effect, which is often
referred to as hormesis, has also been observed in worms, as
mild heat-shock and oxidative stress result in a small but signi-
ficant extension in lifespan (Lithgow et al., 1995; Cypser &
Johnson, 2002). Therefore, while our results strongly suggest
that celecoxib and its derivatives might extend lifespan by
inhibiting PDK-1 activity, we cannot rule out the possibility that
the increased longevity is the result of a hormetic effect
induced by the cytotoxicity of celecoxib, because high doses of
celecoxib do cause lethality.
It is noteworthy that the external concentrations of celecoxib
that extend lifespan (2–10 lM) are very close to the maximum
serum concentration (1.8 ± 0.6 lM) found in osteoarthritis
patients who were orally administered 200 mg celecoxib
(Itthipanichpong et al., 2005). The internal concentration of cel-
ecoxib that extends lifespan in worms, however, is likely to be
ten- to 100-fold lower than external concentrations (Rand &
Johnson, 1995; Evason et al., 2005).
In addition to its use as an anti-inflammatory drug for the
treatment of rheumatoid arthritis and osteoarthritis, celecoxib
has been shown to exert potent anticancer activities as well.
Several epidemiological, preclinical, and clinical studies have
shown that regular use of celecoxib significantly reduce the
risk of multiple cancers, including colorectal, pancreatic, lung,
skin, and breast cancers [reviewed in (Kismet et al., 2004)].
For instance, it has been shown in recent clinical trials that cel-
ecoxib is very effective in preventing colorectal adenomatous
polyps (Arber et al., 2006; Bertagnolli et al., 2006). In addition
to its role in cancer prevention, celecoxib appears to be effec-
tive in treating tumors that have already formed [reviewed in
(Gasparini et al., 2003)]. Despite these ongoing clinical investi-
gations, the molecular mechanism underlying celecoxib-medi-
ated antitumor effects in vivo remains unclear. While
celecoxib can inhibit COX-2 and can cause cell cycle arrest
and apoptosis in certain cancer cells, accumulating evidence
suggest that inhibition of COX-2 may not play a dominant
role in this drug’s anticancer effects. For instance, it has been
shown that the antitumor effect of celecoxib can be obtained
in cancer cells that do not express COX-2 (Grosch et al.,
2001; Chuang et al., 2008). Furthermore, a structure–function
analysis of several dozens of celecoxib analogs reveals that the
antitumor potency is not dependent on its COX-2 inhibitory
activity (Zhu et al., 2002, 2004). Interestingly, these findings
are consistent with our observations in C. elegans, as celecox-
ib also delays the progression of tumor growth, likely in a
COX-2-independent manner. Considering recent studies asso-
ciating celecoxib use with a higher risk of cardiovascular
events (Solomon et al., 2005), celecoxib derivatives such as
OSU-03012 that target PDK-1 specifically may be a more suit-
able candidate for future development of anticancer or even
antiaging drugs.
Celecoxib or OSU-03012 treatment in worms also delays the
onset of polyQ-mediated protein aggregation and proteotoxic-
ity (Fig. 7A–B). This beneficial effect may be the result of a
direct inhibition of a mechanism that normally promotes aging
(e.g. IIS pathway) by the drugs. Thus, the age-dependent pro-
gression of polyQ proteotoxicity is delayed when the rate of
aging is reduced. Alternatively, celecoxib may act on a specific
target that independently controls the development of aggre-
gate-mediated proteotoxicity. In humans, epidemiological stud-
ies have shown that long-term use of NSAIDs reduces the risk
and delays the onset of Alzheimer’s disease as well as other
neurodegenerative diseases (Aisen, 2002; Asanuma et al.,
2004). Recent studies have reported that a subset of NSAIDs
can lower the production of amyloidigenic Ab42 or Ab40 pep-
tides, potentially independent of its COX inhibitory activity
(Weggen et al., 2001; Gasparini et al., 2004). However, nonse-
lective NSAIDs appear to be more effective than selective COX-
2 inhibitors in protection from Ab toxicity. Moreover, clinical
trails so far have failed to show any beneficial effect of celecox-
ib in AD (Firuzi & Pratico, 2006).
Overall, our results support a model that celecoxib and its
derivative OSU-03012 act through PDK-1, a conserved compo-
nent of the IIS pathway, to extend lifespan in C. elegans. These
findings may serve as a starting point for developing new thera-
peutics combating various aging-related diseases.
Experimental procedures
Strains
All strains used were maintained and handled as described
previously (Brenner, 1974). CF1037: daf-16(mu86)I, DA1116:
eat-2(ad1116)II, CF1041: daf-2(e1370)III, JT9609: pdk-
1(sa680)X, GR1318: pdk-1(mg142)X; TJ356: zIs356 [Ex(daf-
16::gfp + rol-6)], BR2773: byEx[sgk-1::gfp],AM140: rmI-
s132[unc-54p::Q35::yfp].
Pharmacological compounds
Celecoxib was extracted from Celebrex capsules obtained from
Amerisource Health (Malvern, PA, USA) with ethyl acetate fol-
lowed by recrystallization from a mixture of ethyl acetate and
hexane. 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-
1H-pyrazol-1-yl]-phenyl] acetamide (OSU-03012) was synthe-
sized by Dr. Chen’s laboratory as described previously (Zhu
et al., 2004). These compounds were dissolved in DMSO for
storage and diluted in water before use. Compounds at various
concentrations were added to the NG plates approximately 8–
12 h before transferring animals onto these drug-containing
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plates. The final DMSO concentration was kept at 0.1% after
adding drugs to the plates.
RNA interference experiments
HT115 bacteria transformed with RNAi vectors (L4440) express-
ing dsRNA of the genes indicated were grown at 37 C in LB
with 10 lg mL)1 tetracycline and 50 lg mL)1 carbenicillin, then
seeded onto NG-carbenicillin plates, and supplemented with
100 lL of 0.1 M IPTG. Eggs were added to plates and transferred
to new plates every 3–6 days.
Lifespan analysis
Lifespan analysis was conducted at 15 or 20 C as described
previously (Kenyon et al., 1993; Apfeld & Kenyon, 1999).
Strains were grown at 20 C for at least two generations with-
out starvation before used in lifespan analysis. At least 60
worms were used for each experiment. In all experiments, the
prefertile period of adulthood was used as t = 0 for lifespan
analysis. Statview 5.01 (SAS Institute) software was used for
statistical analysis to determine the means and percentiles. In
all cases, P values were calculated using the log-rank (Mantel–
Cox) method. For a typical drug treatment experiment, unless
indicated otherwise, parental worms were cultured in the pres-
ence of the drug, and progeny were selected at the L4 stage
to start the experiments. Thus, these worms were exposed to
the drug from fertilization until death. To ensure that the
drugs retain its potency throughout the entire experiment, ani-
mals were transferred to fresh plates with the same drugs
every 2–4 days.
DAF-16 nuclear localization assay
For quantification of DAF-16::GFP localization, synchronized
eggs from TJ356 animals (i.e. transgenic animals–expressing
DAF-l6::GFP) were seeded onto either DMSO control or rele-
vant drug plates. The GFP expression was then analyzed using
an Olympus BX61 (Olympus America Inc., Center Valley, PA,
USA) fluorescent microscope at 40· or 100· magnifications.
Using a blind assay, worms were scored for the presence or
absence of GFP accumulation within the intestinal nuclei as 1-
day-old adult (n = 120 or greater for all treatments). An ani-
mal was scored as having nuclear GFP if more than one intesti-
nal nuclei contained DAF- 16-GFP. Lifespans following each
treatment were analyzed to confirm the effectiveness of each
drug treatment.
Quantitative RT-PCR analysis
To measure the mRNA level of sod-3 in drug-treated animals,
total RNA was isolated from approximately 5000 Day 1 adult
worms grown on either control or drug-containing NG plates.
cDNA was then prepared from 4 lg of total RNA using Super-
script III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA ).
TaqMan real-time PCR experiments were then performed in
using the Chromo 4 system (MJ Research). Relative mRNA level
of sod-3 was calculated and normalized against the internal con-
trol (act-1, the b-actin). Primer and probe sequences are available
upon request.
Immunoprecipitation and Western blotting analysis
Worm extracts were prepared from Day1 adult BR2773
(sgk-1::gfp) worms grown on either control or drug-containing
HG plates. Animals were harvested and washed two times with
cold M9 buffer. Animals were then washed once with homo-
genization buffer (HB buffer, 20 mM Hepes, pH 7.6, 100 mM
NaCl, 10 mM KCl, 1.5 mM, MgCl2, 0.1 mM EDTA, 0.5 mM EGTA,
44 mM Sucrose, 0.5% Trion X-100). The worm pellet was resus-
pended in 3· volume of HB buffer with 1.5 mM NaF, 2 mM
Na2VO4, and protease inhibitors mix (Roche, Basel, Switzerland).
The worm pellet was then lysed by applying to the freeze-and-
thaw cycle twice. The lysate was transferred into a Dounce
homogenizer and stroked 30 times with a B pestle. The lysate
was collected and spun at 14 000 g for 20 min. The superna-
tant was collected, and protein concentration was measured by
Bradford assay (Pierce, Thermo Fisher Scientific, Rockford, IL,
USA ).
For immunoprecipitation experiments, 2.5 mg of total pro-
tein was first incubated with rabbit polyclonal anti-GFP anti-
body (Abcam, Cambridge, UK #6556) at 1:500 dilution for 3–
5 h at 4 C. Forty microliters of 50% protein A-agarose slurry
was then added to the extract and incubated for another 3–
5 h at 4 C. The beads were washed three times with TNTG
buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Triton X-100,
10% glycerol) with protease inhibitors. After the final wash,
the beads were boiled with SDS sample buffer for Western
blotting analysis using respective antibodies. The mouse mono-
clonal anti-phospho (Ser ⁄ Thr)-PDK-1 docking motif antibody
(#9634) and the rabbit polyclonal anti-phosphothreonine anti-
body (#9381) were purchased from Cell Signaling Technology,
Danvers, MA, USA . The mouse monoclonal anti-phosphoser-
ine antibody was purchased from Sigma-Aldrich, St. Louis,
MO, USA (#P3430).
polyQ aggregation quantitation
Approximately 200 synchronized eggs of Q35-yfp-expressing
animals were placed on plates containing OSU-03012 or
DMSO control. Animals were then transferred to fresh plates
with the same drugs every 3–4 days. From each group, 10–15
worms were randomly selected to be scored for aggregates
every day. Animals selected were viewed at 100· magnifica-
tion with a stereomicroscope equipped for epifluorescence.
Images of these animals were taken, and the number of
aggregates in each animal was blindly counted by three inde-
pendent observers after all the images have been collected.
Aggregates were defined as discrete structures with clear
boundaries on all sides.
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Mobility assay
The spontaneous locomotion speed was measured using an
automated worm tracking system as previously described (Hsu
et al., 2009).
DAPI staining for gld-1()) tumor formation
Day 6 adult worms grown on gld-1 RNAi bacteria and treated
with different drugs were collected and fixed with cold metha-
nol at )20 C for 30 min. The fixed samples were then incu-
bated with 100 ng mL)1 of DNA-intercalating dye 4¢,6¢-
diamidino-2-phenylindole (DAPI) for 20 min. After washing by
M9 buffer, the breaking out of the germ cells from gonads was
visualized and scored using fluorescence microscopy.
Dauer formation assay
daf-2 (e1370)animals were grown on plates containing DMSO,
celecoxib, or OSU-03012 at 20 C, F1 eggs were incubated at
22.5 or 25 C, and animals were scored for dauer arrest 72 h
later.
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